Avantor, Inc.AVTREarnings & Financial Report
Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania. Established in 1904 as J.T. Baker, the company changed its name to Avantor in 2010. Avantor went public in 2019 and is now listed on the New York Stock Exchange under the symbol “AVTR”.
AVTR Q4 FY2025 Key Financial Metrics
Revenue
$1.7B
Gross Profit
$523.9M
Operating Profit
$126.4M
Net Profit
$52.4M
Gross Margin
31.5%
Operating Margin
7.6%
Net Margin
3.1%
YoY Growth
-1.4%
EPS
$0.08
Avantor, Inc. Q4 FY2025 Financial Summary
Avantor, Inc. reported revenue of $1.7B (down 1.4% YoY) for Q4 FY2025, with a net profit of $52.4M (down 89.5% YoY) (3.1% margin). Cost of goods sold was $1.1B, operating expenses totaled $397.5M.
Key Financial Metrics
| Total Revenue | $1.7B |
|---|---|
| Net Profit | $52.4M |
| Gross Margin | 31.5% |
| Operating Margin | 7.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Avantor, Inc. Q4 FY2025 revenue of $1.7B breaks down across 2 segments, led by Laboratory Solutions Segment at $1.1B (67.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Laboratory Solutions Segment | $1.1B | 67.1% |
| Bioscience Production Segment | $547.5M | 32.9% |
Avantor, Inc. Revenue by Segment — Quarterly Trend
Avantor, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Laboratory Solutions Segment and Bioscience Production Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Laboratory Solutions Segment | $1.1B | $1.1B | $1.1B | $1.1B |
| Bioscience Production Segment | $547.5M | $527.3M | $561.3M | $516.4M |
Avantor, Inc. Annual Revenue by Year
Avantor, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.6B).
Avantor, Inc. Quarterly Revenue & Net Profit History
Avantor, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.7B | -1.4% | $52.4M | 3.1% |
| Q3 FY2025 | $1.6B | -5.3% | $-711.8M | -43.8% |
| Q2 FY2025 | $1.7B | -1.1% | $64.7M | 3.8% |
| Q1 FY2025 | $1.6B | -5.9% | $64.5M | 4.1% |
| Q4 FY2024 | $1.7B | -2.1% | $500.4M | 29.7% |
| Q3 FY2024 | $1.7B | -0.3% | $57.8M | 3.4% |
| Q2 FY2024 | $1.7B | -2.4% | $92.9M | 5.5% |
| Q1 FY2024 | $1.7B | -5.6% | $60.4M | 3.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.68B | $1.70B | $1.71B | $1.69B | $1.58B | $1.68B | $1.62B | $1.66B |
| YoY Growth | -5.6% | -2.4% | -0.3% | -2.1% | -5.9% | -1.1% | -5.3% | -1.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.76B | $12.69B | $12.84B | $12.11B | $12.33B | $12.78B | $11.68B | $11.79B |
| Liabilities | $7.43B | $7.26B | $7.29B | $6.16B | $6.23B | $6.49B | $6.11B | $6.23B |
| Equity | $5.34B | $5.43B | $5.55B | $5.96B | $6.10B | $6.29B | $5.57B | $5.57B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $141.6M | $281.1M | $244.8M | $173.3M | $109.3M | $154.4M | $207.4M | $152.7M |